Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now later-stage tilt small index

Nocturia: later-stage trial registry

5 of 10 indexed Nocturia trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Nocturia: 10 US clinical trials tracked, 5 recruiting.

Nocturia is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Ferring Pharmaceuticals, running 3 of these trials.

Enrollment posture brief

Registry condition nocturia

OPEN 5 | RECR 50% | LATE 7 | EARLY 0 | RANK #1724 | SPON 3

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Nocturia (this)50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Nocturia

Nocturia lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Nocturia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Nocturia is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Nocturia research.

    Ferring Pharmaceuticals accounts for 3 of 10 trials (30%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Nocturia enrolment sits around 192 participants.

    Median target enrolment is 192 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.

  4. Nocturia research is mostly interventional.

    10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 34Phase 43

Open and recent trials

10 total, page 1 of 1

RECRUITING NA 596 participants

APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women

Medstar Health Research Institute

NCT06797245

RECRUITING NA 192 participants

Multi-center Trial to Improve Nocturia and Sleep in Older Adults

Atlanta VA Medical Center

NCT06110091

RECRUITING Phase 4 120 participants

Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women

Shachi Tyagi

NCT05604222

RECRUITING Phase 4 60 participants

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

University of South Florida

NCT04305743

RECRUITING NA 36 participants

Mandibular Advancement Device and Changes in Nocturia

Fernanda Yanez Regonesi

NCT05562388

COMPLETED Phase 3 799 participants

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Ferring Pharmaceuticals

NCT00477490

COMPLETED Phase 3 554 participants

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Ferring Pharmaceuticals

NCT00615836

COMPLETED Phase 3 376 participants

Long Term Safety Assessment of SER120 in Patients With Nocturia

Serenity Pharmaceuticals

NCT00981682

COMPLETED Phase 4 60 participants

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

Idorsia Pharmaceuticals

NCT05597020

COMPLETED Phase 3 56 participants

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

Ferring Pharmaceuticals

NCT01552343

Phase Distribution

PhaseTrial count
Phase 3 4
Phase 4 3

Named interventions

Most-linked intervention names on Nocturia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
3 trials
SER120 Drug
1 trials
Desmopressin Melt Drug
1 trials
desmopressin acetate Drug
1 trials
AUGS Patient Handouts Behavioral
1 trials
RiSolve App Device
1 trials
Brief Behavioral Treatment for Insomnia Behavioral
1 trials
Health Education Program Behavioral
1 trials

US sites by state

Facility locations filed on Nocturia trials. A trial with sites in several states counts in each.

Florida 5 trials
California 5 trials
Texas 2 trials
South Carolina 2 trials
Pennsylvania 2 trials
North Carolina 2 trials
Massachusetts 2 trials
Illinois 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Nocturia page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Nocturia condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.